Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_assertion type Assertion NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_head.
- NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_provenance.
- NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_assertion evidence source_evidence_literature NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_provenance.
- NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_assertion SIO_000772 18089823 NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_provenance.
- NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_assertion wasDerivedFrom befree-2016 NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_provenance.
- NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_assertion wasGeneratedBy ECO_0000203 NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_provenance.